Targeted immune interventions for type 1 diabetes: Not as easy as it looks!

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 4, 2014, Pages 271-278

  Rigby, Mark R ^a   Ehlers, Mario R ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Immune Tolerance Network   (United States)

Author keywords

autoantibodies; autoantigens; immune therapy; regulatory T cells; T cells; type 1 diabetes

Indexed keywords

ABATACEPT; ALEFACEPT; AUTOANTIGEN; AZATHIOPRINE; C PEPTIDE; CANAKINUMAB; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INSULIN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; OTELIXIZUMAB; PLACEBO; PREDNISONE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TEPLIZUMAB; THYMOCYTE ANTIBODY; CD27 ANTIGEN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; TREATMENT RESPONSE; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; IMMUNOLOGY; TRENDS;

ANTIGENS, CD27; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INSULIN; INSULIN-SECRETING CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 84903754137     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000075     Document Type: Review

References (97)

1. Imperatore G, Boyle JP, Thompson TJ, et al. Projections of type 1 and type 2 diabetes burDen in the U.S. population aged 2 years through 2050: dynamic moDeling of inciDence, mortality, and popul ation growth Diabetes Care,2012,35,2515-2520
2. Patterson CC, Dahlquist GG, Gyurus E, et al. InciDence trends for childhood type 1 diabetes in Europe during 1989- 2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373:2027-2033.
3. JDRF. Type 1 diabetes facts; http://jdrf.org/about-jdrf/fact-sheets/type- 1-diabetes-facts/2014 [Accessed 1 March 2014].
4. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464:1293-1300.
5. Dawson SI, Willis J, Florkowski CM, Scott RS. All-cause mortality in insulintreated diabetic patients: a 20-year follow-up. Diabetes Res Clin Pract 2008; 80:e6-e9.
6. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine Deficiencies. Lancet 1974; 2:1279-1283.
7. Haskins K, Wegmann D. Diabetogenic T-cell clones. Diabetes 1996; 45:1299-1305. (Pubitemid 26332890)
8. Bottazzo GF, Dean BM, McNally JM, et al. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985; 313:353-360. (Pubitemid 15046367)
9. Wong FS,Karttunen J,Dumont C,et al,IDentification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library,Nat Med,1999,5,1026-1031. (Pubitemid 29439573)
10. Eisenbarth GS. Type 1 diabetes: molecular, cellular and clinical immunology. Adv Exp Med Biol 2004; 552:306-310. (Pubitemid 40103428)
11. La Torre D, Lernmark A. Immunology of beta-cell Destruction. Adv Exp Med Biol 2010; 654:537-583.
12. Van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011; 91:79-118.
13. Atkinson MA, Bluestone JA, Eisenbarth GS, et al. How does type 1 diabetes Develop: the notion of homiciDe or beta-cell suiciDe revisited. Diabetes 2011; 60:1370-1379.
14. EVans-Molina C, Hatanaka M, Mirmira RG. Lost in translation: endoplasmic reticulum stress and the Decline of beta-cell health in diabetes mellitus. Diabetes Obes Metab 2013; 15 (Suppl 3):159-169. Excel lcent review of how ER stress may contribute not only to type 2 but type 1 diabetes.
15. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009; 360:1646-1654.
16. Barker JM, Barriga KJ, Yu L, et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004; 89:3896-3902. (Pubitemid 39071491)
17. Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in diabetes. Diabetes 2005; 54 (Suppl 2):S52-S61. (Pubitemid 43343331)
18. Reijonen H, Daniels TL, Lernmark A, Nepom G T. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 2000; 49:1621-1626.
19. Orban T, Sosenko JM, Cuthbertson D, et al. Pancreat ic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 32:2269-2274.
20. DiLorenzo TP, Serreze DV. The good turned ugly: immunopathogenic basis for diabetogenic CD8 T cells in NOD mice. Immunol Rev 2005; 204:250-263. (Pubitemid 40460506)
21. Amrani A, Verdaguer J, Serra P, et al. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 2000; 406:739-742.
22. Walter U, Santamaria P. CD8 T cells in autoimmunity. Curr Opin Immunol 2005; 17:624-631.
23. Peterson LD, Van Der Keur M, De Vries RR, Roep BO. Autoreactive and immunoregulatory T-cell subsets in insulin-DepenDent diabetes mellitus. Diabetologia 1999; 42:443-449. (Pubitemid 29148403)
24. Arif S, Tree TI, Astill TP, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113:451-463. (Pubitemid 38544189)
25. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209:51-60.
26. Ortis F, Pirot P, Naamane N, et al. Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia 2008; 51:1213-1225.
27. Argiles JM, Lopez-Soriano J, Lopez-Soriano FJ. Cytokines and diabetes: the final step Involvement of TNF-alpha in both type I and II diabetes mellitus. Horm Metab Res 1994; 26:447-449. (Pubitemid 24336934)
28. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-DepenDent diabetes mellitus. Diabetes Metab Rev 1998; 14:129-151. (Pubitemid 28346261)
29. Danke NA, Yang J, Greenbaum C, Kwok WW. Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. J Autoimmun 2005; 25:303-311. (Pubitemid 41642977)
30. Viglietta V,Kent SC,Orban T,Hafler DA, GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes,J Clin Invest,2002,109,895-903. (Pubitemid 34275110)
31. Abbas AK, Benoist C, Bluestone JA, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 2013; 14:307-308.
32. Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009; 229:41-66.
33. Miyara M, Sakaguchi S. Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns. Immunol Cell Biol 2011; 89:346-351.
34. Wildin RS, R amsDell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27:18-20. (Pubitemid 32044512)
35. D'Alise AM, Auyeung V, Feuerer M, et al. The Defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci USA 2008; 105:19857-19862.
36. Kasprowicz DJ, Smallwood PS, Tyznik AJ, Ziegler SF. Scurfin (FoxP3) controls T-DepenDent immune responses in vivo through regulation of CD4+ T cell effector function. J Immunol 2003; 171:1216-1223. (Pubitemid 36900050)
37. Ziegler SF. FOXP3: of mice and m en. Annu Rev Immunol 2006; 24:209-226.
38. Buckner JH. Mechanisms of impaired regulation by CD4(+)CD25(+) FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10:849-859.
39. Sgouroudis E, Albanese A, Piccirillo CA. Impact of protective IL-2 allelic variants on CD4+ Foxp3 regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. J Immunol 2008; 181:6283-6292.
40. Lindley S, Dayan CM, Bishop A, et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54:92-99. (Pubitemid 40105099)
41. Brusko TM, Wasserfall CH, Clare-Salzler MJ, et al. Functional Defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005; 54:1407-1414. (Pubitemid 40586671)
42. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008; 8:523-532.
43. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all traDes, master of regulation. Nat Immunol 2008; 9:239-244. (Pubitemid 351267321)
44. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40:1830- 1835.
45. Cabrera SM, Rigby MR, Mirmira RG. Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med 2012; 12:1261-1272.
46. SchneiDer A, Rieck M, Sanda S, et al. The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 2008; 181:7350-7355.
47. Haseda F, Imagawa A, Murase-Mishiba Y, et al. CD4(+ ) CD45RA(-) Fox-P3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin Exp Immunol 2013; 173:207-216.
48. B ougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318:663-670. (Pubitemid 18083606)
49. Carel JC, Boitar d C, Eisenbarth G, et al. Cyclosporine Delays but does not prevent clinical onset in glucose intolerant pretype 1 diabetic children. J Autoimmun 1996; 9:739-745. (Pubitemid 27047023)
50. Silverstein J, Maclaren N, Riley W, et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-DepenDent diabetes mellitus. N Engl J Med 1988; 319:599-604.
51. Bougneres PF,Landais P,Boisson C,et al,Limited duration of remission of insulin DepenDency in children with recent overt type I diabetes treated with low-dose cyclosporin,Diabetes,1990,39,1264-1272. (Pubitemid 20327064)
52. Harrison LC, Colman PG, De an B, et al. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 1985; 34:1306-1308. (Pubitemid 16186833)
53. Bresson D, Togher L, Rodrigo E, et al. Ant i-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006; 116:1371-1381.
54. Peakman M, von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 2010; 59:2087-2093.
55. Sarikonda G, Sachithanantham S, Manenkova Y, et al. Transient B-cell Depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. PLoS One 2013; 8:e54712.
56. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005; 28:1068-1076. (Pubitemid 40616615)
57. Diabetes Prevention Trial-Type 1 Diabetes Study G. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346:1685-1691.
58. Nanto-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372:1746-1755.
59. Thrower SL, James L, Hall W, et al. Proinsulin peptiDe immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009; 155:156-165.
60. Huurman VA, Decochez K, Mathieu C, et al. Therapy with the hsp60 peptiDe DiaPep277 in C-peptiDe positive type 1 diabetes patients. Diabetes Metab Res Rev 2007; 23:269-275. (Pubitemid 46851467)
61. Huurman VA, Van Der MeiDe PE, Duinkerken G, et al. Immunological efficacy of heat shock protein 60 peptiDe DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 2008; 152:488-497. (Pubitemid 351661507)
62. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptiDe (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358:1749-1753. (Pubitemid 33152998)
63. Axelsson S, Hjorth M, Akerman L, et al. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65). Diabetes Metab Res Rev 2010; 26:559-568.
64. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366:433-442.
65. Hjorth M, Axelsson S, RyDen A, et al. GAD-alum treatment induces GAD65-specific CD4+CD25 high FOXP3+ cells in type 1 diabetic patients. Clin Immunol 2011; 138:117-126.
66. Axelsson S, Cher amy M, Akerman L, et al. Cellular and humoral immune responses in type 1 diabetic patients participating in a Phase III GAD-alum Intervention Trial. Diabetes Care 2013; 36:3418-3424.
67. Hu CY, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117:3857-3867. (Pubitemid 350224095)
68. Pescovitz MD, Greenbaum CJ, Kra use-Steinrauf H, et al. Rituximab, Blymphocyte Depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-2152.
69. Pescovitz MD, Torgerson TR, Ochs HD, et al. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011; 128:1295.e5-1302.e5.
70. Dunger A, Sch roDer D, Augstein P, et al. Impact of metabolic activity of beta cells on cytokine-induced damage and recovery of rat pancreatic islets. Acta Diabetol 1995; 32:217-224. (Pubitemid 26007462)
71. Kawahara DJ, Kenney JS . Species differences in human and rat islet sensitivity to human cytokines. Monoclonal antiinterleukin-1 (IL-1) influences on direct and indirect IL-1-mediated islet effects. Cytokine 1991; 3:117-124.
72. M astrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, doubleblind study. Diabetes Care 2009; 32:1244-1249.
73. Moran A,Bundy B,Becker DJ,et al,Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebocontrolled trials,Lancet,2013,381,1905-1915. Although a report of 2 ' negative' T1D clinical trials, is an important addition to translating potential therapies from proclincal moDels to humans.
74. Glandt M, Hagopian W, Herold KC. Treatment of type 1 diabetes with anti-CD3 monoclonal antibody. Rev Endocr Metab Disord 2003; 4:361-368. (Pubitemid 37493652)
75. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-1698. (Pubitemid 34547482)
76. Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptiDe responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline iDentify a subgroup of responDers. Diabetes 2013. Important study suggesting that there may be differential responsiveness to immune therapu in subpopulations with new-onset T1D. Encouraging need for more stu dies of human T1D.
77. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 37 8:487-497.
78. Tolerx Ga. GlaxoSmithKline and Tolerx announce phase III DEFEND-1 study of otelixizumab in type 1 diabetes did not meet its primary endpoint; 2011 [cited 2011 March 11].
79. Ambe ry P, Donner TW, Biswas N, et al. Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptiDe secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multice ntre study. Diabet Med 2013. Important large-scale pase III clincal trial scaling up what were thought to be postive phase II trials.
80. Green JM, Noel PJ, Sperling AI, et al. T cell costimulation through the CD28 receptor. Proc Assoc Am Physicians 1995; 107:41-46.
81. Herold KG, Lenschow DJ, Bluestone JA. CD28/B7 regulation of autoimmune diabetes. Immunol Res 1997; 16:71-84. (Pubitemid 27129630)
82. Lenschow DJ, Herold KC, Rhee L, et al. CD28/B7 regulation of Th1 and Th2 subsets in the Development of autoimmune diabetes. Immunity 1996; 5:285-293. (Pubitemid 26341371)
83. Rigby MR, Trexler AM, Pearson TC, Larsen CP. CD28/CD154 blockaDe prevents autoimmune diabetes by inducing nonDeletional tolerance after effector t-cell inhibition and regulatory T-cell expansion. Diabetes 2008; 57:2672-2683.
84. Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockaDe of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006 ; 6 (5 Pt 1):876-883. (Pubitemid 44356637)
85. Lundquist L. Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis. Adv Ther 2007; 24:333-345. (Pubitemid 46988377)
86. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378:412-419.
87. McCall M, Shapiro AM. Update on islet transplantation. Cold Spring Harb Perspect Med 2012; 2:a007823.
88. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven pat ients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343:230-238. (Pubitemid 30490390)
89. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al. Failure to preser ve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010; 33:826-832.
90. Ugrasbul F, Moore WV, Tong PY, Kover K L. Prevention of diabetes: effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat. Pediatr Diabetes 2008; 9:596-601.
91. Cheng G, Yu A, Malek TR. T-cell tolerance and the multifunctional role of IL-2R signaling in T-regulatory cells. Immunol Rev 2011; 241:63-76.
92. Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012; 61:2340-2348.
93. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, et al. Combination therapy with sirolimus and in terleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002; 51:638-645. (Pubitemid 34760170)
94. Gitelman SE,Gottlieb PA,Rigby MR,et al,Antithymocyte globulin treatment for pati ents with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial,Lancet Diab Endocrinol,2013, 1,306-316.
95. Rigby MR, DiMeglio LA, RenDell MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diab Endocrinol 2013; 1:284-294.
96. Roep BO, Atkinson M, von Herrath M. Satisfaction(not) guaranteed: reevaluating the use of animal moDels of type 1 diabetes. Nat Rev Immunol 2004; 4:989-997. (Pubitemid 39620073)
97. Ehlers MR, Nepom GT. Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience. Rev Diabet Stud 2012; 9:359-371.